Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris

Circulation

Volumn 94, Issue 7, 1996, Pages 1503-1505

  Van Boven, Ad J ^a,c   Jukema, J Wouter ^c,d   Zwinderman, Aeilko H ^b,c   Crijns, Harry J G M ^a,c   Lie, Kong I ^a,c   Bruschke, Albert V G ^c,d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

cholesterol; drugs; electrocardiography; ischemia

Indexed keywords

ANTIANGINA PECTORIS AGENT; CHOLESTEROL; PLACEBO; PRAVASTATIN;

ADULT; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAPHY MONITORING; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029778439     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.7.1503     Document Type: Article

References (14)

1. Stern S, Tzivoni D. Early detection of silent ischaemic heart disease by 24-hour electrocardiographic monitoring of active subjects. Br Heart J. 1974;36:481-486.
2. Deanfield JE, Shea M, Ribiero P, de Landsheere CM, Wilson RA, Horlock P, Selwyn AP. Transient ST-segment depression as a marker of myocardial ischemia during daily life. Am J Cardiol. 1984; 54:1195-1200.
3. Kunkes SH, Pichard AD. Smith H, Gorlin R, Herman MV, Kuper-smith J. Silent ST segment deviations and extent of coronary artery disease. Am Heart J. 1980;100:813-820.
4. Rocco MB, Nabel EG, Campbell S, Goldman L, Barry J, Mead K, Selwyn AP. Prognostic importance of myocardial ischemia detected by ambulatory monitoring in patients with coronary disease. Circulation. 1988;78:877-884.
5. Yeung AC, Barry J, Orav J, Bonassin E, Raby KE, Selwyn AP. Effects of asymptomatic ischemia on long-term prognosis in chronic stable coronary disease. Circulation. 1991;83:1598-1604.
6. Gill JB, Cairns JA, Roberts RS, Constantini L, Sealy BJ, Fallen EF, Tomlinson CW, Gent M. Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction. N Engl J Med. 1996;334:65-70.
7. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary artery disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-1307.
8. The Scandinavian Simvasiatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
9. Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, van Rappard FM, Lie KI, on behalf of the REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Stalin Study (REGRESS). Circulation. 1995;91:2528-2540.
10. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
11. Pepine CJ, Singh B, Gibson R, Kent K. NHLBI Workshop: working conference on recognition, pathogenesis, and management options in silent coronary artery disease: report group IV, management options. Circulation. 1987;75(suppl II):II-52-II-53.
12. Zwinderman AH. A generalized Rasch model for manifest predictors. Psychometrika. 1991;56:589-600.
13. Zwinderman AH. Statistical analysis of longitudinal quality of life data with missing measurement. Qual Life Res. 1992;3:512-521.
14. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP, Latifi R, Dudrick SJ. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. Circulation. 1994;89:1530-1538.